BTIG Says Buy Ophthotech (OPHT) Ahead of Upcoming Fovista Data

September 20, 2016 7:30 AM EDT
Get Alerts OPHT Hot Sheet
Price: $4.86 --0%

Rating Summary:
    4 Buy, 9 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 10 | New: 3
Trade OPHT Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

BTIG recommends to scoop-up shares of Ophthotech (Nasdaq: OPHT) ahead of data from two Fovista phase 3s. The firm reiterates OPHT at Buy with a price target of $92.

Analyst Ling Wang commented, Although conventional wisdom generally suggests a smaller treatment delta going from Phase II to III, we expect a similar or larger treatment delta, given the trend of Phase IIb data over time and durable efficacy of Fovista suggested in a Phase II anti-fibrosis trial. A competing product from Regeneron (REGN, Neutral, Analyst: Dane Leone), REGN 2176-3 (Phase II data by YE16), is not a meaningful threat, in our view.

For an analyst ratings summary and ratings history on Ophthotech Corp click here. For more ratings news on Ophthotech Corp click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities


Add Your Comment